GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Myriad Genetics Inc (LTS:0K3W) » Definitions » Cyclically Adjusted Revenue per Share

Myriad Genetics (LTS:0K3W) Cyclically Adjusted Revenue per Share : $12.02 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Myriad Genetics Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Myriad Genetics's adjusted revenue per share for the three months ended in Mar. 2024 was $2.249. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $12.02 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Myriad Genetics's average Cyclically Adjusted Revenue Growth Rate was 0.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 6.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 7.70% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 12.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Myriad Genetics was 22.90% per year. The lowest was 6.70% per year. And the median was 16.45% per year.

As of today (2024-06-01), Myriad Genetics's current stock price is $22.59. Myriad Genetics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $12.02. Myriad Genetics's Cyclically Adjusted PS Ratio of today is 1.88.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Myriad Genetics was 9.92. The lowest was 1.13. And the median was 3.23.


Myriad Genetics Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Myriad Genetics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myriad Genetics Cyclically Adjusted Revenue per Share Chart

Myriad Genetics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.27 24.16 11.92 10.99 12.00

Myriad Genetics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.56 11.86 11.79 12.00 12.02

Competitive Comparison of Myriad Genetics's Cyclically Adjusted Revenue per Share

For the Diagnostics & Research subindustry, Myriad Genetics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Myriad Genetics's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Myriad Genetics's Cyclically Adjusted PS Ratio falls into.



Myriad Genetics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Myriad Genetics's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=2.249/131.7762*131.7762
=2.249

Current CPI (Mar. 2024) = 131.7762.

Myriad Genetics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 2.426 100.560 3.179
201409 2.218 100.428 2.910
201412 2.446 99.070 3.254
201503 2.436 99.621 3.222
201506 2.612 100.684 3.419
201509 2.545 100.392 3.341
201512 2.619 99.792 3.458
201603 2.592 100.470 3.400
201606 2.339 101.688 3.031
201609 2.580 101.861 3.338
201612 2.877 101.863 3.722
201703 2.883 102.862 3.693
201706 2.264 103.349 2.887
201709 2.540 104.136 3.214
201712 2.613 104.011 3.311
201803 2.529 105.290 3.165
201806 2.660 106.317 3.297
201809 2.771 106.507 3.428
201812 2.834 105.998 3.523
201903 2.892 107.251 3.553
201906 2.880 108.070 3.512
201909 2.528 108.329 3.075
201912 2.622 108.420 3.187
202003 2.201 108.902 2.663
202006 1.249 108.767 1.513
202009 1.944 109.815 2.333
202012 2.061 109.897 2.471
202103 2.278 111.754 2.686
202106 2.453 114.631 2.820
202109 2.053 115.734 2.338
202112 2.007 117.630 2.248
202203 2.059 121.301 2.237
202206 2.230 125.017 2.351
202209 1.938 125.227 2.039
202212 2.190 125.222 2.305
202303 2.229 127.348 2.307
202306 2.246 128.729 2.299
202309 2.343 129.860 2.378
202312 2.275 129.419 2.316
202403 2.249 131.776 2.249

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Myriad Genetics  (LTS:0K3W) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Myriad Genetics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=22.59/12.02
=1.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Myriad Genetics was 9.92. The lowest was 1.13. And the median was 3.23.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Myriad Genetics Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Myriad Genetics's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Myriad Genetics (LTS:0K3W) Business Description

Traded in Other Exchanges
Address
320 Wakara Way, Salt Lake City, UT, USA, 84108
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.

Myriad Genetics (LTS:0K3W) Headlines

No Headlines